Get started
Author

Matthew Tall

A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
2012 · Udai Banerji, Leni van Doorn, et al. · Clinical Cancer Research · 78
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma
2015 · Mike I. Walton, Paul D. Eve, et al. · Oncotarget · 69
PDF
Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.
2011 · A. Biondo, T. A. Yap, et al. · Journal of Clinical Oncology · 20
Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors.
2014 · Paul Elvin, Amy Palmer, et al. · Journal of Clinical Oncology · 7
Abstract CT111: Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial
2024 · Simon Pacey, Ching Leung, et al. · Cancer Research · 5
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors.
2010 · U. Banerji, L. van Doorn, et al. · Journal of Clinical Oncology · 4
Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade
2010 · Timothy A. Yap, Kyriakos Papadopoulos, et al. · Cancer Research · 3
Abstract B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors
2023 · Udai Banerji, Simon Pacey, et al. · Molecular Cancer Therapeutics · 2
Supplementary Figure 1 from A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
2023 · Udai Banerji, Leni van Doorn, et al.
Data from A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
2023 · Udai Banerji, Leni van Doorn, et al.
Data from A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
2023 · Udai Banerji, Leni van Doorn, et al.
Supplementary Materials from A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
2023 · Udai Banerji, Leni van Doorn, et al.
Supplementary Materials from A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
2023 · Udai Banerji, Leni van Doorn, et al.
PDF
Supplementary Figure 1 from A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
2023 · Udai Banerji, Leni van Doorn, et al.
PDF
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma
2016 · Mike I. Walton, Paul D. Eve, et al. · Newcastle University ePrints (Newcastle Univesity)
394 A phase I dose escalation and pharmacological study of the novel class I selective histone deacetylase inhibitor CHR-3996, in patients with advanced or treatment refractory solid tumours
2010 · F. Eskens, L. van Doorn, et al. · European Journal of Cancer Supplements
Works count: 16
Citation count: 188
H-index: 5
I10-index: 3
Year
Topic
Type